OA
NKTR icon

OFI Advisors’s Nektar Therapeutics NKTR Stock Holding History

OFI Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$344K Sell
2,091
-19,321
-90% -$3.42M 0.02% 918
2015
Q2 		$4.02M Buy
+21,412
New +$3.68M 0.24% 80

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OFI Advisors's NKTR Position: Q3 2015 in Review

OFI Advisors reduced its Nektar Therapeutics (NKTR) stake by 90% in Q3 2015, selling an estimated $3.42M and leaving 2,091 shares worth $344K. The position accounts for 0.02% of the portfolio, ranked #918.

OFI Advisors first reported a position in NKTR in Q2 2015 and has held it in 2 quarters since. The position peaked at $4.02M in Q2 2015. 166 funds tracked by Wall St. Rank hold NKTR as of Q3 2015.

  • OFI Advisors held 2,091 shares of Nektar Therapeutics worth $344K as of Q3 2015.
  • OFI Advisors sold 19,321 Nektar Therapeutics shares in Q3 2015, an estimated $3.42M.
  • Nektar Therapeutics made up 0.02% of OFI Advisors's portfolio in Q3 2015, its #918 holding.
  • OFI Advisors first reported a position in Nektar Therapeutics in Q2 2015 and has held it in 2 quarters since.
  • OFI Advisors's Nektar Therapeutics position peaked at $4.02M in Q2 2015.
  • 166 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2015.

Based on OFI Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.